Oral contraceptives and hernostasis

Gynecological Endocrinology

Volumn 10, Issue sup2, 1996, Pages 49-57

  Klufr, C ^a  

^a TNO   (Netherlands)

Author keywords

Cardiovascular Disease; Factor V Leiden Mutation; Hemostasis; Oral Contraceptives

Indexed keywords

EID: 0345384498     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513599609045628     Document Type: Article

References (41)

1. Winkler U. H. Menopause, hormone replacement therapy and cardiovascular disease: a review of hemostaseological findings. Fibrinolysis 1922; 6 (Suppl. 3) 5 – 10
2. Fruzzetti F., Ricci C., Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994; 49: 579 – 92
3. Girolami A., Paolo S., Bruno G., Luigi S. Oral contraceptive therapy causes an increased and not a decreased resistance to APC. Blood Coagul. Fibrinol. 1994; 6: 143 – 4
4. Vandenbroucke J. P., Koster T., Briët E., Reitsma P. H., Bertina R. M., Rosendaal F. R. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453 – 7
5. Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet 1995; 346: 1133 – 4
6. Pabinger I., Schneider B., and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary Antithrombin III-, Protein C- and Protein S-deficiency taking oral contraceptive preparation. Thromb. Haemostas. 1994; 71: 548 – 52
7. Spek C. A., Koster T., Rosendaal F. R., Bertina R. M., Reitsma P. H. Genotype variation in the promotor region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 214 – 18
8. Huisveld L. A., Hospers J. E. H., Meijers J. C.M., Starkenburg A. E., Erich W. B. M., Bouma B. M. Oral contraceptives reduce total protein S, but not free protein S. Thromb. Res. 1987; 45: 109 – 14
9. Daume E. Influence of modem low-dose oral contraceptives on hemostasis. Adv. Contracept. 1990; 6: 51 – 68, (Suppl.)
10. Koster T. Deep-Vein Thrombosis. A population-based case—control study. Leiden Thrombophilia Study. Thesis Leiden University. 1995
11. Kluft C. Disorders of the haemostatic system and the risk of development of thrombotic and cardio-vascular diseases: limitations of laboratory diagnosis. Am, J. Obstet. Gynecol. 1990; 163: 305 – 12
12. Pedersen O. D., Munkvad S., Gram J., Kluft C., Jespersen J. Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. Eur. Heart J. 1993; 14: 785 – 9
13. Fowkes F. G. R., Lowe G. D. O., Housley E., Rattray A., Rumley A., Elton R. A., MacGregor I. R., Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84 – 6
14. Ridker P. M., Hennekens C. H., Cerskus A., Stampfer M. J. Plasma concentration of cross-linked fibrin degradation products (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236 – 40
15. Thompson S. G., Kienast J., Pyke S. D.M., Haverkate F., van de Loo J. C.W., for the European Concerted Action on Thrombosis and Disabilities, Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N. Engl. J. Men. 1995; 332: 635 – 41
16. Fowkes F. G. R., Connor J. M., Smith F. B., Wood J., Donnan P. T., Lowe G. D.O. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693 – 6
17. Bara L., Nicaud V., Tiret L., Cambien F., Samama M. M., on behalf of the EARS group. Expression of a paternal history of premature myocardial infarction on fibrinogen, Factor VIIc and PAI-1 in European offspring - the EARS study. Thromb. Haemostas. 1994; 71: 434 – 40
18. Eriksson P., Kallin B., van 't Hooft F. M., Bavenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA 1995; 92: 1851 – 5
19. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med. 1995; 332: 912 – 17
20. Van der Bom J. G., de Knijff P., Bots M. L., Haverkate F., Hofman A., Kluft C., Grobbee D. E. Polymorphism of the blood clot lysis enzyme tissue-type plasminogen activator is associated with myocardial infarction. Circulation 1995; 92 (Suppl. I) 30 – 1
21. Bloemenkamp K. W.M., Gevers Leuven J. A., Helmerhorst F. M., Dersjant-Roorda M. C., de Boer R., Meijer P., Spielmann D., Kluft C. In low-dose oral contraceptives containing 20 μg or 30 μ g ethinylestradiol, gestodene is associated with a lower increase in coagulant factor VII than is desogestrel. Gynecol. Endocrinol. 1996; 10 (Suppl. 2) 145 – 8
22. Task force on oral contraceptives. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br. J. Obstet. Gynaecol. 1991; 98: 1117 – 28
23. Abbate R., Pinto S., Rostagno C., Bruni V., Rosati D., Mariani G. Effects of long-term gestodene-containing contraceptive administration on hemostasis. Am. J. Obstet. Gynecol. 1990; 163: 424 – 30
24. Morrissey J. H. Tissue factor interactions with factor VII: measurement and clinical significance of factor Vila in plasma. Blood Coagul. Fibrinol 1995; 6 (Suppl. 1) S14 – S19
25. Jespersen J., Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen. Levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator. Thromb. Haemostas. 1985; 54: 454 – 9
26. Kluft C. Fibrinolysis risk markers for cardiovascular disease. Gynecol. Endocrinol 1993; 7: 45 – 53, (Suppl.)
27. Kluft C., Gevers Leuven J. A., Helmerhorst F. M. Studies on the mechanisms of action of steroids on coagulation and fibrinolysis. Sex Steroids and the Cardiovascular System, P. Ramwell, G. Rubanyi, E. Schillinger. Schering Foundation Workshop 5, Springer, Berlin 1992; 95 – 110
28. Gevers Leuven J. A., Kluft C., Dersjant-Roorda M. C., Harthoorn-Lasthuizen E. J., de Boer R., Helmerhorst F. M. Effects of low dose oral contraceptives differing in progestogen compound on coagulation and fibrinolytic risk variables for venous and arterial thromboembolic diseases. Fibrinolysis and Disease, Molecular and Hemovascular Aspects of Fibrinolysis, P. Glas-Greenwalt. CRC Press. 1995; 226 – 34, Chapter 32
29. Mackie I. J., Segal H., Burren T., Gallimore M., Walshe K. J., Robinson G., Machin S. J. Heparin cofactor II levels are increased by the use of combined oral contraceptives. Blood Coagul Fibrinol 1991; 1: 647 – 51
30. Daly L., Bonnar J. Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am. J. Obstet. Gynecol 1990; 163: 430 – 7
31. Bonnar J. Changes in coagulation and fibrinolysis with low dose oral contraceptives. Adv. Contracept. 1991; 7 (Suppl. 3) 285 – 91
32. Winkler U. H., Koslowski S., Oberhoff C., Schindler E. M., Schindler A. E. Changes of the dynamic equilibrium of hemostasis associated with the use of low-dose oral contraceptives: a controlled study of cyproterone acetate containing oral contraceptives combined with either 35 or 50 μg ethinyl estradiol. Adv. Contracept. 1991; 7 (Suppl. 3) 273 – 84
33. Campbell S. J., Mackie I. J., Robinson G. E., Machin S. J. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill. Br. J. Obstet., Gynaecol. 1993; 100: 79 – 84
34. Petersen K. R., Skouby S. O., Sidelmann J., Mølsted-Pedersen L., Jespersen J. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am. J. Obstet. Gynecol 1994; 171: 400 – 5
35. Nieuwenhuizen W. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review. Blood Coagul. Fibrinol 1993; 4: 93 – 6
36. Nossel H. L. Relative proteolysis of the fibrinogen B β-chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981; 291: 165 – 7
37. Gram J., Munkvad S., Jespersen J. Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen. Am. J. Obstet. Gynecol 1990; 163: 438 – 42
38. Mannucci P. M., Tripodi A., Bottasso B., Baudo F., Finazzi G., De-Stefano V., Palareti G., Manotti C., Mazzucconi M. G., Castaman G. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb. Haemostas. 1992; 67: 200 – 2
39. David J. L., Demeyer F., Gillain D., Gaspard U. Haemostasis global profile during monophasic oral contraception by norgestimate or desogestrel associated to low-dose ethinylestradiol. Gynecol. Endocrinol 1996; 10 (Suppl. 2) 137 – 9
40. Schrauwen Y., de Vries R. E.M., Kooistra T., Emeis J. J. Acute release of tissue-type plasminogen activator (t-PA) from the endothelium; regulatory mechanisms and therapeutic target. Fibrinolysis 1994; 8 (Suppl. 2) 8 – 12
41. Brussaard H. E., Gevers Leuven J. A., Emeis J. J., Kluft C., Krans H. M.J. Effect of short term postmenopausal estrogen replacement therapy in women with non-insulin dependent diabetes mellitus on endothelial function variables in blood. Gynecol. Endocrinol. 1996; 10 (Suppl. 2) 173 – 7